Home
overview

The Ophthalmic Drugs Conference is returning for the 6th edition, taking place on the 20th-21st of November 2023, in London.

Register Today to get the Early Bird Rate Offer

What’s different this year?

Advances in ophthalmic medicine are needed as our population ages. In this course, we'll discuss ophthalmic drug delivery, cell and gene therapies, and conditions such as diabetic retinopathy, age-related macular degeneration, and glaucoma and help you shape the future of ophthalmology.

The only event that will:
The conference will be a variety of novel drugs and delivery techniques showing you promising clinical data. Other key areas will be gene therapy and artificial Intelligence with developments on the latest drug pipelines and clinical trials for you to expand your ophthalmic medicine portfolios. 

 

  • Assess new industry directions through the latest data from ophthalmic clinical trials
  • Review advanced techniques in treating age-related diseases of ophthalmology
     
  • Explore evolving therapeutic potential in previously undruggable diseases through innovative gene therapies
     
  • Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field
     
  • Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D

 

 

Here's a taste of who's already attending:

  • Bayer
  • AbbVie
  • Novarits
  • Roche
  • Johnson & Johnson
  • OcuTerra
  • Boehringer Ingelheim
  • MSD

& Many others

Join us by registering today! 

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

Mitchell A deLong, Scientific Advisor, Alcon

clock

9:10

Overview of regulatory landscape for ophthalmic drug developments

Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

  • Overview of current regulatory framework relating to ophthalmic medicines.
  • Updates on recent ophthalmic drug approvals and latest guidances. 
  • Introduction to devices and combination approaches for novel ocular therapeutics. 

     

  • clock

    9:50

    Lessons in regulatory guidance for ophthalmic medical devices

    Ruth Lloyd-Williams

    Ruth Lloyd-Williams, Benefit Risk Evaluation Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)

  • Risk management and ISO 14971
  • A look at some important international standards for ophthalmic products
  • Guidance on best practices for clinical investigation applications
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    PANEL DISCUSSION: Reviewing the evolving landscape of ophthalmic drugs R&D

  • An industry outlook into recent industry advances in ophthalmic drugs
  • Potential for novel partnerships or business models to advance R&D in ophthalmics
  • Thoughts on next generation approaches to improve ophthalmic drug discovery and development
  • Richard Reschen, Director, Business Development & Licencing, MSD

    Kerrie Brady, CEO, OcuTerra Therapeutics

    Prabhu Velusami, Senior Director, Johnson & johnson

    Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

    clock

    11:40

    Recent Developments in Suprachoroidal Microneedle-based Drug and Gene Delivery

    Viral Kansara

    Viral Kansara, Vice President of Preclinical Development, Clearside Biomedical

  • Suprachoroidal injection as a promising route of delivery for chorioretinal diseases
  • SCS Microinjector platform: Safety, Durability and Compartmentalized delivery
  • Preclinical and clinical proof of concept for SCS gene therapy and small molecule suspensions
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Exploring Recent Developments in the Potential of Port Delivery Systems

    Dany Dauletbekov, Medical Director, Roche

  • Expanding on benefits of the port delivery system
  • Exploring the latest clinical data
  • Overcoming the most frequent challenges of the port delivery system
  • Delving into the opportunities for more specific drug targeting via port delivery systems going forward
  • clock

    14:00

    New Technologies in Diabetic Retinopathy Management

    David Tanzer, Chief Medical Officer, OcuTerra Therapeutics

  • Redefining Diabetic Retinopathy – from standard 7-field color fundus photos to non-invasive 3D assessment of peripheral vasculature
  • Screening and Diagnostics – earlier detection means improved treatment options; structure vs. function
  • Treatment – from old gold standard IVT to non-invasive options, allowing for acceptable earlier intervention
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Advancements in the treatment of diabetic retinopathy

  • Steps to overcome R&D hurdles in the treatment of diabetic retinopathy
  • An overview of current strategies in the treatment of early-stage retinal disease
  • Expanding on VEGF as a disease target in diabetic retinal diseases
  • clock

    15:50

    Enhancing understanding of ophthalmic disease progression through key imaging techniques

    Lakshmi Rajagopalan

    Lakshmi Rajagopalan, Principal Scientist, AbbVie

  • An introduction to retinal imaging and optic nerve disorders
  • Understanding non-human primates as an efficient model for imaging technologies
  • A review of recent advances in imaging technologies and next steps in overcoming key challenges
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    Mitchell A deLong, Scientific Advisor, Alcon

    Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Mitchell A deLong, Scientific Advisor, Alcon

    Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

    clock

    9:10

    Combating ocular inflammation

    Mitchell A deLong, Scientific Advisor, Alcon

  • The search for eff ective non-steroidal anti-infl amatory agents for non-infectious inflammation
  • JAK inhibition as an ocular anti-infl ammatory mechanism
  • Pre-clinical results of selective JAK inhibitors in animal models of ocular inflammation
  • clock

    9:50

    Insights into clinical trial design strategies for novel ophthalmic drugs

    Bernhard Maag

    Bernhard Maag, Head Ophthalmology, Novartis

  • Enhancing trial design through defined trial end point
  • A review of biomarkers as an eff ective drug target in clinical trials
  • Improving patient centricity via increased visual fi eld trial end points
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Transforming the treatment landscape for AMD and DMO with novel technologies

    LOIC LHUILLIER, COO, Exonate

  • Exploring modulation of alternative splicing as a new treatment modality
  • Expanding on VEGF as a therapeutic target through VEGF isoforms
  • Lessons learned from preclinical discovery and shaping the clinical development strategy
  • Overview of the in-patient Phase I trial
  • clock

    11:40

    Strengthening the therapeutic landscape for inherited retinal diseases using genome editing with AAV vectors and CRISPR/Cas9 technologies

    Daniel Chung, Chief Medical Officer, Sparing Vision

  • Expanding on the clinical development of novel gene therapies including SPVN06
  • The benefi ts of designing gene therapies to act independently of the causative gene mutation
  • An introduction to new clinical trials and future workings
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Omlonti: the novel EP2-receptor agonist for glaucoma / OHT treatment

    Naj Sharif, Vice President, Global Alliances & External Research, Santen Inc. USA

  • Role of EP2-receptor agonism in lowering intraocular pressure
  • Non-prostaglandin (PG) and PG EP2-receptor agonists
  • Diff erentiating properties of Omlonti as a non-PG EP2 agonist
  • Clinical experience and effi cacy of Omlonti in OHT/glaucoma patients
  • clock

    14:00

    Dry AMD: Opportunities and Challenges

    Prabhu Velusami, Senior Director, Johnson & johnson

  • Overview of pathogenesis and natural history of dry AMD
  • Lessons from recent clinical trial results in geographic atrophy
  • Overview of gene therapy approaches to treat geographic atrophy
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Retinal Genetic Therapy

    Aniz Girach, Chief Medical Officer, ProQR Therapeutics

  • Retinal cell/gene/RNA therapy trial design
  • Key Endpoints used in cell/gene/RNA therapy trials
  • Clinical significance thresholds for key endpoints
  • Regulatory framework for approval of genetic therapies

     

  • clock

    15:50

    Non-clinical safety strategies for AAV-delivered gene therapies

    Mark  Singh

    Mark Singh, Non-Clinical Manager, Cell and Gene Therapy Catapult

  • A brief introduction to ATMPs, and of the use of the risk-based approach.
  • Discussion of the various non-clinical considerations of a fictional AAV gene therapy.
  • Discussion of the various biological aspects to be considered when developing a non-clinical strategy for AAV gene therapies.
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two

    Peter Morgan-Warren, Director, Global Medical Lead, Ophthalmology, Bayer PLC

    Mitchell A deLong, Scientific Advisor, Alcon


    Chief Medical Officer
    ProQR Therapeutics
    Head Ophthalmology
    Novartis
    Chief Medical Officer
    Sparing Vision
    Medical Director
    Roche
    Chief Medical Officer
    OcuTerra Therapeutics
    CEO
    OcuTerra Therapeutics
    Principal Scientist
    AbbVie
    COO
    Exonate
    Non-Clinical Manager
    Cell and Gene Therapy Catapult
    Scientific Advisor
    Alcon
    Vice President, Global Alliances & External Research
    Santen Inc. USA
    Director, Global Medical Lead, Ophthalmology
    Bayer PLC
    Senior Director
    Johnson & johnson
    Director, Business Development & Licencing
    MSD
    Benefit Risk Evaluation Assessor
    Medicines & Healthcare Products Regulatory Agency (MHRA)
    Vice President of Preclinical Development
    Clearside Biomedical

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Speaker Presentation - Petra Kozma

    Download

    Brochure

    Download

    Past Speaker Presentation - Mitchell De Long

    Download

    Past Speaker Presentation - Kate Binley

    Download

    Past Speaker Presentation - Marion Munk

    Download

    Speaker Interview - David Tanzer

    Download

    Speaker Interview- Mark Singh

    Download

    Speaker Interview - Daniel Chung

    Download

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out